The effects of ginger on type 2 diabetes

The effects of ginger on insulin resistance, lipid profile & lipoproteins in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104246278N1

Enrollment

Registered

2011-06-03

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes

Interventions

Intervention 1: control: capsules 1 gr microcristalin cellulose, 3times per day. Intervention 2: intervention: capsules ginger 1 gr 3timea per day.

Treatment - Drugs

control: capsules 1 gr microcristalin cellulose, 3times per day

intervention: capsules ginger 1 gr 3timea per day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with type 2 diabetes ,patients newly diagnosed diabetes to 10 years, no pregnancy and lactation, lack of vitamin and mineral supplementation, without any thyroid , kidney , CVD diseases and not using TG & cholesterol lowering drugs,and also using ESTROGEN or PROGESTRON, FBS<180, 2Hpp<250 . Exclusion criteria: using insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;Fasting insulin. Timepoint: Before and 2 months after intervention. Method of measurement: mU/L.;Fructose amin. Timepoint: Before and 2 months after intervention. Method of measurement: microm/L.;HbA1C. Timepoint: Before and 2 months after intervention. Method of measurement: %.;TG. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;LDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;HDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;LDL-C/HDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: -.;APO-A1. Timepoint: Before and 2 months after intervention. Method of measurement: ng/dl.;APO-B100. Timepoint: Before and 2 months after intervention. Method of measurement: ng/dl.;Insulin resistance, sensitivity. Timepoint: Before and 2 months after intervention. Method of measurement: -.;-. Timepoint: -. Method of measurement: -.	—

Measure

Time frame

FBS. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;Fasting insulin. Timepoint: Before and 2 months after intervention. Method of measurement: mU/L.;Fructose amin. Timepoint: Before and 2 months after intervention. Method of measurement: microm/L.;HbA1C. Timepoint: Before and 2 months after intervention. Method of measurement: %.;TG. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;LDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;HDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: mg/dl.;LDL-C/HDL-C. Timepoint: Before and 2 months after intervention. Method of measurement: -.;APO-A1. Timepoint: Before and 2 months after intervention. Method of measurement: ng/dl.;APO-B100. Timepoint: Before and 2 months after intervention. Method of measurement: ng/dl.;Insulin resistance, sensitivity. Timepoint: Before and 2 months after intervention. Method of measurement: -.;-. Timepoint: -. Method of measurement: -.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Mohammad Mohammadi

Yazd Diabetes Research Center

mozaffari.kh@gmail.com+98 35 1525 8234

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026